A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 8, 2000, Pages 2046-2051

  Drusano, G L ^a   Preston, S L ^a   Van Guilder, M ^b   North, D ^c   Gombert, M ^d   Oefelein, M ^e   Boccumini, L ^f   Weisinger, B ^g   Corrado, M ^f   Kahn, J ^g  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Long Beach Medical Center   (United States)

^e WRIGHT PATTERSON AIR FORCE BASE   (United States)

^f Advanced Biologics   (United States)

^g Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHLAMYDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG PENETRATION; ESCHERICHIA COLI; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DEMOGRAPHY; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; OFLOXACIN; PROSTATE; PROSTATITIS;

EID: 0033944132     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.8.2046-2051.2000     Document Type: Article

References (9)

1. Aagaard, J., and P. O. Madsen. 1997. Bacterial prostatitis: new methods of treatment. Urology 37(Suppl.):4-8.
2. Barza, M., and G. Cuchural. 1985. General principles of antibiotic tissue penetration. J. Antimicrob. Chemother. 15(Suppl. A):59-75.
3. Cars, O. 1981. Tissue distribution of ampicillin: assays in muscle tissue and subcutaneous tissue cage fluid from normal and nephrectomized rabbits. Scand. J. Infect. Dis. 13:283-289.
4. Chien, S. C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
5. Child, J., D. Mortiboy, J. M. Andrews, A. T. Chow, and R. Wise. 1995. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob. Agents Chemother. 39:2749-2751.
6. D'Argenio, D. Z., and A. Schumitzky, 1995. ADAPT II user's guide. University of Southern California, Los Angeles. Calif.
7. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, F. A. Wong, and M. Corrado. 1998. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob. Agents Chemother. 42:1098-1104.
8. Schumitzky, A. 1991. Nonparametric EM algorithms for estimating prior distributions. Appl. Math. Comput. 45:141-157.
9. Siegrist, H. H., M.-C. Nepa, and A. Jacquet. 1999. Susceptibility to levofloxacin of clinical isolates of bacteria from intensive care and haematology/oncology patients in Switzerland: a multicentre study. J. Antimicrob. Chemother. 43(Suppl. C):51-54.